Lyra Therapeutics, once buoyed by promising Phase 3 trial data for its LYR-210 nasal implant targeting chronic rhinosinusitis (CRS), has abruptly suspended further development following mixed clinical outcomes. The failure of ENLIGHTEN 1 to meet primary endpoints and the subsequent workforce reductions underscored operational strains intensified by a Nasdaq delisting and capped liquidity resources. Despite a positive ENLIGHTEN 2 readout, regulatory mandates for additional trials coupled with minimal revenue streams and ongoing strategic review cloud near-term recovery prospects. The company confronts challenging capital allocation decisions and an eroded equity base while holding modest intellectual property over localized anti-inflammatory drug delivery technology.